NASH Treatment Market Poised for Robust Growth, But Faces Hurdles in Diagnosis and Access
• Global NASH drug market projected to reach $48.3B by 2035, indicating 18% CAGR between 2023-2035 • North America to generate largest revenue share amid rising NASH treatment expenditures and diagnoses • Europe to see highest 18.6% CAGR due to increasing obesity rates • IQVIA estimates NASH treatment market could surpass $100B by 2030, but faces barriers like low diagnosis rates • Crowded pipeline - Novo Nordisk, Gilead, Inventiva, Galectin among companies with late-stage assets; Lilly, Ionis, others reported positive Phase 2 data recently